These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
777 related articles for article (PubMed ID: 19887624)
1. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624 [TBL] [Abstract][Full Text] [Related]
2. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up. Destro A; Ceresoli GL; Baryshnikova E; Garassino I; Zucali PA; De Vincenzo F; Bianchi P; Morenghi E; Testori A; Alloisio M; Santoro A; Roncalli M Lung Cancer; 2008 Mar; 59(3):369-76. PubMed ID: 17920725 [TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Zhong S; Fields CR; Su N; Pan YX; Robertson KD Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644 [TBL] [Abstract][Full Text] [Related]
5. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242 [TBL] [Abstract][Full Text] [Related]
6. Molecular changes in mesothelioma with an impact on prognosis and treatment. Jean D; Daubriac J; Le Pimpec-Barthes F; Galateau-Salle F; Jaurand MC Arch Pathol Lab Med; 2012 Mar; 136(3):277-93. PubMed ID: 22372904 [TBL] [Abstract][Full Text] [Related]
7. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230 [TBL] [Abstract][Full Text] [Related]
8. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Tsou JA; Shen LY; Siegmund KD; Long TI; Laird PW; Seneviratne CK; Koss MN; Pass HI; Hagen JA; Laird-Offringa IA Lung Cancer; 2005 Feb; 47(2):193-204. PubMed ID: 15639718 [TBL] [Abstract][Full Text] [Related]
9. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055 [TBL] [Abstract][Full Text] [Related]
10. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. Kassis ES; Zhao M; Hong JA; Chen GA; Nguyen DM; Schrump DS J Thorac Cardiovasc Surg; 2006 Feb; 131(2):298-306. PubMed ID: 16434257 [TBL] [Abstract][Full Text] [Related]
11. Genetics of malignant pleural mesothelioma: molecular markers and biologic targets. Bueno R; Gordon GJ Thorac Surg Clin; 2004 Nov; 14(4):461-8. PubMed ID: 15559052 [TBL] [Abstract][Full Text] [Related]
12. A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes. Shiraishi M; Sekiguchi A; Terry MJ; Oates AJ; Miyamoto Y; Chuu YH; Munakata M; Sekiya T Oncogene; 2002 May; 21(23):3804-13. PubMed ID: 12032849 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651 [TBL] [Abstract][Full Text] [Related]
15. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Ylagan LR; Zhai J Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333 [TBL] [Abstract][Full Text] [Related]
16. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850 [TBL] [Abstract][Full Text] [Related]
17. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693 [TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Toyooka S; Pass HI; Shivapurkar N; Fukuyama Y; Maruyama R; Toyooka KO; Gilcrease M; Farinas A; Minna JD; Gazdar AF Cancer Res; 2001 Aug; 61(15):5727-30. PubMed ID: 11479207 [TBL] [Abstract][Full Text] [Related]
19. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922 [TBL] [Abstract][Full Text] [Related]
20. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter. Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]